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Previous work has suggested that the LIGHT-TR2 co-
stimulatory pathway plays a role in the acute and chronic 
stages of dextran sulfate sodium (DSS)-induced colitis  
[Steinberg et al. (2008); Wang et al. (2005)]. To clarify the 
role of TNFR-related 2 (TR2) signaling in the maintenance 
of intestinal homeostasis, we generated a TR2 knock-out 
(KO) mouse. Using DSS to induce colitis, we compared the 
colitic symptoms and pathological changes in wild type 
(WT) and TR2 KO mice, and the production of cytokines by 
the diseased colons. We also studied the role of TR2 in 
suppressing innate and adaptive immunity in the DSS 
model. TR2 deficient mice were characterized by reduced 
symptoms of intestinal inflammation compared with wild-
type mice, and reduced production of cytokines. We there-
fore generated a monoclonal antibody against mouse TR2 
which was specific to TR2 and capable of blocking TR2 
signals. With this antibody, we demonstrated that antago-
nizing TR2 during the development of DSS-induced colitis 
reduced the symptoms of inflammation. Our findings sug-
gest that TR2 is an important mediator in colitis, and may 






Inflammatory bowel disease (IBD), which includes ulcerative 
colitis and Crohn’s disease (CD), leads to long term, and some-
times irreversible, impairment of gastrointestinal structure and 
function (Bouma and Strober, 2003). Impaired mucosal barrier 
function, innate and adoptive immunity, pro-inflammatory and 
immunoregulatory cytokines, and activation of lymphocytes and 
macrophages, have all been implicated in the pathogenesis of 
IBD (Axelsson et al., 1996; Blumberg et al., 1999; Chae et al., 
2010).  
Proteins belonging to the TNF/TNFR superfamily play multi-
ple roles in the activation and homeostasis of immune cells. 
LIGHT is a member of the TNF family that is capable of binding 
to herpes virus entry mediator (HVEM), lymphotoxin beta re-
ceptor (LTβR), and soluble decoy receptor 3 (DcR3/TR6), all of 
which are members of TNFR family. LIGHT is expressed on 
immature dendritic cells (DC) and activated T cells (Wan et al., 
2002). TNFR-related 2 (TR2, HVEM, or TNFRSF-14) is ex-
pressed on many immune cells, including T, B, and NK cells, as 
well as endothelial cells; it is a receptor for three TNF super-
family ligands; LIGHT, glycoprotein D (gD) of herpes simplex 
virus (HSV) and lymphotoxin alpha (LTα) (Mauri et al., 1998).  
Signaling through TR2 promotes growth and proliferation and 
the production of cytokines such as interleukin-2 (IL-2), inter-
feron-γ (IFN-γ), and TNF-α (Croft, 2003; Wan et al., 2002). 
Costimulation by LIGHT modulates the effect of TR2 on T cell-
mediated immune responses in tumors, graft-versus-host dis-
ease (GVHD), and graft rejection (Tamada et al., 2000).  
The dextran sulphate sodium (DSS)-induced colitis model is 
a well-characterized animal model of colitis. It has been shown 
to have histological relevance to human ulcerative colitis, in-
cluding focal crypt lesions, mucosal and submucosal inflamma-
tion, and granulocyte infiltration (Bauma and Strober, 2003). 
Although the cause of DSS-induced colitis is unclear, it may 
result from the toxic effects of DSS on colonic epithelial cells 
and alterations in luminal bacterial flora. In the acute stages of 
DSS-induced colitis, the T cell response consists of a polarized 
T helper type 1 (TH1) response, but during the later and more 
chronic phase of inflammation, a mixed TH1/TH2 response oc-
curs (Egger et al., 2000).  
Recent studies show that LIGHT is involved in DSS-induced 
colitis. Transgenic mice (Tg) with enhanced LIGHT expression 
on T cells developed colitis (Wang et al., 2001). Also, when 
LIGHT Tg mesenteric lymph node cells were adoptively trans-
ferred to RAG-/- mice, the recipients developed CD, and TH1 
cytokines including IFN-γ, IL-12, IL-2, and TNF-α were the main 
cause of the symptoms (Wang et al., 2005). Effects of the in-
teraction of LIGHT and its receptor LTβR (Stopfer et al., 2004), 
and of TR2, on the acute and chronic stages of DSS-induced 
colitis have been suggested by previous studies (Steinberg et 
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In the present study we used DSS to induce colitis in WT and 
TR2 KO mice, and compared the resulting colitic symptoms 
and pathological changes, as well as the production of cyto-
kines by the diseased colons.  
 
MATERIALS AND METHODS 
 
Mice 
Wild type C57BL/6 mice (8-12 weeks old) were purchased from 
the Jackson Laboratory. All mice were maintained under spe-
cific pathogen-free conditions in the animal facilities of the Uni-
versity of Ulsan.  
 
Production of TR2 knock-out (KO) mice 
A mouse genomic chromosome clone containing the TR2/ 
HVEM locus was isolated from a 129/SvEv bacteriophage li-
brary using a TR2-specific probe derived from the TR2 mRNA 
sequence (muTR2: 5′-ATGGCCTGAGCAAGTGTCTGC-3′; and 
Int3Rev: 5′-ACACACCCTGAGAACCTGCCCAC-3′). In the tar-
geting vector, a 4.8-kb fragment extending from the KpnI site in 
intron 4 to the HindIII site in intron 9 was replaced by the neo 
gene in pJNS2 (Goulet et al., 1994). This construct was elec-
troporated into ES cells as described previously, and neomycin- 
and ganciclovir-resistant colonies were identified (Goulet et al., 
1994). DNA was isolated from surviving colonies, digested with 
KpnI, and analyzed by Southern blotting using a probe down-
stream of the targeting construct (Supplementary Fig. 1A). 
Chimeric mice were generated from the TR2-targeted ES cell 
lines and bred with B6D2 mice. The offspring were genotyped 
by Southern blot analysis of tail DNA, using the probe de-
scribed above, and heterozygous mice were backcrossed 12 
times into the C57BL/6 strain.  
 
Production of anti-mTR2 antibody 
Mouse TR2 (145-645 bp; extra cellular domain, ECD) was 
cloned into pGEX-6T-1 vector from cDNA using the primer pair 
(sense; ccctcatgcagaca, antisense; tgggaggagcaggt). The cloned 
DNA was transformed into E. coli BL21. Glutathione-S-transfer-
ase (GST)-TR2 fusion protein was induced by IPTG and puri-
fied with a glutathione-agarose column. Sprague-Dawley rats 
were subcutaneously immunized with purified GST-TR2 protein 
emulsified in complete Freund’s adjuvant, and intravenous (i.v) 
immunized with the same purified GST-TR2 protein for the last 
7 days. Spleen cells from the immunized rat were fused with 
mouse myeloma cells (SP20) and hybridoma cells were tested 
by ELISA for production of antibodies against recombinant TR2 
protein. The TR2 mAb (9A3) was identified as Rat IgG2b, κ 
using an Immunopure Monoclonal Antibody Isotyping kit I 
(Pierce). To measure TR2 expression on spleen and lymph 
node cells in vitro, cells from TR2 WT and TR2 KO mice were 
stained with fluorescein isothiocyanate (FITC)-conjugated anti-
TR2 and phycoerythrin (PE)-conjugated anti-CD4+ (L3T4; BD 
Phamingen™) after blocking with Fc receptor-blocking mAb 
2.4G2 for 10 min at 4°C. TR2 expression was then analyzed 
with a FACS Caliber (Becton Dickinson. USA).  
 
T cell proliferation assay 
TR2+/+ CD4+ and TR2-/- CD4+ T cells were collected as single-
cell suspensions of splenocytes or lymph node (LN) cells and 
enriched by positive selection using magnetic anti-CD4 mi-
crobeads and a VarioMACS™ magnetic cell sorter. The CD4+ T 
cells (2 × 105 cells/well) were incubated in round plates for 70 hr 
in the presence of 0.25 μg/ml anti-CD3 mAb alone, or in com-
bination with 0.8, 1.6, 3.2, 6.4 and 12.8 μg/ml anti-TR2 mAb. 
The cells were labeled with 0.5 μCi/well (3H)-thymidine for the 
final 16 h, harvested, and counted in a liquid scintillation coun-
ter (Packard, USA).  
 
Induction of acute colitis 
For induction of acute colitis mice received 3% DSS (MW 
36,000-50.000; MP Biomedicals, Inc.) dissolved in drinking 
water for 7 days. For therapeutic studies, mice were injected 
with intraperitoneally (i.p.) with 500 μg blocking anti-TR2 mAb 
or rat IgG as a control on days 0, 2, 4 and 6. Mice were sacri-
ficed five or seven days after DSS treatment, after which the 
colons were removed and submitted for histological examina-
tion, and isolation of cytokines. The body weights of the animals 
were monitored daily for 3 weeks.  
 
Histological analysis 
Colons were snap-frozen in isopentane (2-methylbutane, 
Sigma-Aldrich) and embedded in Tissue-Tek optimal cutting 
temperature (OCT) compound (Sakura Finetek USA, Inc.) in 
liquid nitrogen. Cryostat sections of 6 μm were prepared, 
stained with hematoxylin and eosin (H&E), and mounted in 
glycerol-vinyl-alcohol (GVA) mounting solution (Zymed). 
 
In vivo labeling and in situ staining of proliferating  
intestinal epithelial cells 
5-Bromo-2′-deoxyuridine (BrdU, 20 mg/kg body weight) was 
injected intraperitoneally (i.p) five times at 6-h intervals to mice 
that had been administered 3% DSS for 7 days, and to control 
mice. The colons were removed and fixed in 4% paraformalde-
hyde. Sections of 6 μ were then cut with a cryostat in OCT 
compound and frozen at -80°C. The slides were stained using 
a BrdU In-Situ Detection Kit (BD Pharmingen™), following the 
manufacturer’s instructions. Briefly, the slides were treated in a 
coplin jar containing the working solution of BD Retrievagen A, 
and heated to 89°C in a microwave oven. Binding of bioti-
nylated anti-BrdU antibody was detected with Streptavidin-HRP. 




Supernatants were obtained from pooled colon extracts of 0, 5 
and 7 day DSS-induced mice. Each group contained three 
mice. Cytokines were quantified using a cytometric bead array 
kit (CBA; BD Biosciences) with a FACSCaliber cytometer equi-
pped with Cell-QuestPro and CBA software (BD Biosciences). 
 
Calculation of absolute numbers of lamina propria cells,  
and staining of intracellular cytokines  
Large bowel colons were collected either untreated or after 5 or 
7 days of 3% DSS administration. Lamina propria lymphocytes 
(LPL) were purified as previously described (Kang et al., 2002). 
In brief, stool was removed, and samples were washed with 
RPMI 1640 (Hyclone) and cut into 1 mm lengths. Then they 
were digested with 0.75 mM EDTA in RPMI 1640 and colla-
genase Type 2 (GIBCO) (2 mg/ml collagenase in RPMI 1640). 
The supernatants of the collagenase digests were collected, 
resuspended in 40% Percoll, and loaded onto 75% Percoll 
gradients (Sigma-Aldrich). The interfaces were collected after 
20-min centrifugation at room temperature with the brake off, 
and the cells were washed and used for FACS analysis or in-
tracellular cytokine staining. After washing, total cell numbers 
were counted by hemocytometer, and aliquots were stained 
with FITC-conjugated anti-CD8+ (Ly-2; BD Pharmingen™), or 
anti-MQ (F4/80; eBioscience) and PE-conjugated anti-CD4+ 
(L3T4; BD Pharmingen™) or anti-Gr-1 (RB6-8C5; BD Pharmin- 






























gen™) after blocking with Fc receptor-blocking mAb 2.4G2 for 
10 min at 4C. Intracellular cytokine staining was performed as 
described in the BD Cytofix/Cytoperm™ Kit Manual (BD Biosci-
ences). PE-conjugated IFN-γ (BD Pharmingen) was used for 
intracellular cytokine staining. LPLs purified from WT or TR2 
KO mice were stimulated with 50 ng/ml PMA plus 500 ng/ml 








Generation and analysis of TR2 KO mice 
To characterize the immunological functions of TR2 in vivo, we 
generated TR2 KO mice by genetic targeting as illustrated in 
Supplementary Fig. 1A. Southern blot analysis confirmed dis-
ruption of the gene encoding TR2 in both ES cells and mice, 
after germ-line transmission of the TR2 mutation (Supplemen-
tary Fig. 1B). Northern blot analysis of RNA from TR2/wild type 
(TR2+/+) and KO (TR2-/-) bone marrow cells (Supplementary Fig. 
1C), and flow cytometric analysis (Supplementary Fig. 1D) of 
lymph nodes and splenocytes confirmed that the targeted TR2 
gene contained a null mutation. We also generated an anti-TR2 
antibody, 9A3, and examined its effect on T cell proliferation. 
When CD4+ T cells from TR2+/+ mice were stimulated with anti-
CD3 mAb plus various concentrations of anti-TR2 mAb, meas-
urements of [3H]-thymidine incorporation showed that 9A3 
acted as a blocking antibody for TR2 signal (Supplementary Fig. 
1E). Since the results relating to the generation of TR2 KO 
mouse and mAb against TR2 were very similar to those re-
ported previously (Harrop et al., 1998; Wang et al., 2001), we 
present them in supplementary figures. 
 
Reduced susceptibility in of TR2 deficient mice to  
DSS-induced colits 
To determine the role of TR2 in the development of colitis, we 
induced colitis with DSS in 8 to10 weeks old TR2+/+ and TR2-/- 
mice. Administration of 3% DSS in a drinking water for 7 days 
resulted in epithelial crypt loss, presence of infiltrated cells 
throughout the mucosa, ulceration and mucosal bleeding in 
both TR2+/+ and TR2-/- mice; however, the TR2-/- mice displayed 
reduced and delayed clinical symptoms compared with the 
TR2+/+ mice. The loss of body weight was less severe in the TR2-/ 
- mice compared with that of TR2+/+ mice. Around 7-9 days after 
DSS injection, all of the TR2+/+ mice died whereas all the TR2-/- 
mice survived (Fig. 1A). The TR2-/- mice began to gain weight 
from day 13 and their weight returned to normal by 20 days 
after DSS administration. Similar with the survival rate, the co-
lons were severely shortened by treating DSS in TR2+/+ mice, 
but moderately in TR2-/- mice. The colons of the TR2-/- mice 
were less reduced in length (Fig. 1B). Histological analysis 
again showed that the crypt distortion, the loss of goblet cells, 
and inflammation were more severe in the colons of TR2+/+ 
mice compared with that of TR2-/- mice (Fig. 1C). The inflamma-
tion in the colons of the TR2+/+ mice included massive inflam-
matory response, epithelial erosions and a destruction of the 
crypt structure in the colon, whereas the TR2-/- mice displayed 
epithelial damage but less inflammation and largely intact crypt 
structure (Fig. 1C).  
In a separate experiment, when the TR2+/+ and TR2-/- mice 
were labeled with BrdU 7 days after the DSS administration, we 
found more abundant BrdU-positive cells in the colons of TR2-/- 
mice compared with that of TR2+/+ mice (Fig. 1D).  
 
Delayed infiltration of leukocytes into the lamina propria of 
DSS-administered TR2-/- mice  
As the severity of colitis is co-related with the infiltration of im-
mune cells, the cellular composition of the inflamed colon was 
analyzed in the lamina propria. The number of macrophages 
(F4/80), granulocytes (Ly-6G+) and T-cell subsets (CD4+ and 
CD8+) in the lamina propria of colon was assessed on days 0, 5 
and 7. Before the administration of DSS, there were no differ-
ences in the frequencies of any of the cell types between TR2+/+ 
and TR2-/- mice; the lamina proprias of both mice contained 
comparable levels of macrophages and granulocytes and low 
numbers of lymphocytes. Five days after the DSS administra-
tion, there were marked increases of macrophages and granu-
locytes in the lamina propria of TR2+/+ mice and also T-cells 
Fig. 1. Establishment of an experimental murine
model of colitis. (A) TR2 WT and TR2 KO mice
were administered 3.0% DSS water for 7 days.
Body weight was recorded daily from day 1 to
day 20. (B) Macroscopic appearance of the
dissected colons from TR2 WT (+DSS/TR2
+/+
)
and TR2 KO (+DSS/TR2
-/-
) mice, or control
(-DSS) mice on day 7 of treatment with 3.0%
DSS water. (C) Microscopic views of H&E-
stained sections of colons from TR2 WT and
TR2 KO mice administered DSS for 7 days
(magnification, 20X). (D) Proliferating cells were
detected using BrdU incorporation and anti-
BrdU immunostaining. Positive cells in the
crypts are reddish brown. (magnification, 100X)
Values are means ± s.d. of triplicate samples.
**, P < 0.01, WT versus KO mice. 


















Fig. 2. The DSS-treated TR2 WT and TR2 KO mice were infiltrated 
by leukocytes and granulocytes. Epithelial cells were prepared from 
mice on days 5 and 7 of DSS treatment. The cells were stained with 
FITC-conjugated anti-CD4 and anti-Gr-1, PE-conjugated anti-CD8 
and anti-F4/80, and were quantified by FACS. Values are means ± 
s.d. of 3 independent experiments. *, P < 0.05, cells from WT ver-
sus KO mice. 
 
 
although they were less frequent compared to macrophages 
and granulocytes. Those innate and adaptive immune cells 
were also significantly increased in the laminar propria of TR2-/- 
mice by treating DSS, but the numbers of the infiltrated immune 
cells were significantly less than that of TR2+/+ mice (Fig. 2). 
However, since the leukocyte infiltration into laminar propria 
was swiftly increased in TR2-/- mice, the differences in the infil-
tration between TR2+/+ and TR2-/- mice were no longer sus-
tained 7 days after the DSS administration (Fig. 2). 
 
Delayed expression of inflammatory cytokines in  
DSS-administered TR2-/- mice  
Since we found that the inflammation was delayed in the TR2-/- 
mice after the DSS administration, we wondered whether the 
expression of inflammatory cytokines would be reduced or 
delayed in the absence of TR2. Therefore, we next examined 
the effects of TR2 signaling on the inflammatory cytokine pro-
files in the inflamed colons. Before DSS treatment, there were 
basal levels of cytokines the TR2-/- and TR2+/+ mice. Five days 
after the DSS administration, the expressions of IL-6, MCP-1, 
IFN-γ, and TNF-α were significantly lower in the colons of the 
TR2-/- mice compared with that of the TR2+/+ mice. By day 7, 
the levels of IL-6, MCP-1 and TNF-α were still lower in TR2-/- 
mice compared with that of TR2+/+ mice had much higher 
amounts of IL-6, MCP-1, TNF-α, IL-10 (Fig. 3).  
Since the results were consistent with the survival rate of 
DSS-administered TR2-/- mice, we concluded that the symp-
toms of DSS-induced colitis were moderate in TR2-/- mice due 
to the delayed and reduced inflammation in the absence of TR2 
signaling.  
 
Antagonistic mAb against TR2 ameliorates DSS-induced  
colitis 
Since DSS-induced colitis was ameliorated in the absence of 
TR2 signaling, we further tested the role of TR2 in using the 
blocking antibody for TR2, 9A3. Specific binding of 9A3 mAb to 
TR2 was confirmed using TR2+/+ and TR2-/- T cells as 9A3 did 
not bind to any of the lymphocyte gated LN cells or splenocytes 
from the TR2-/- mice (Supplementary Fig. 1D). Treatment with 
9A3 suppressed in vitro proliferation of CD4+ T cells in a dose-
dependent manner (Supplementary Fig. 1E), suggesting that it 
is an antagonistic antibody. 

























Fig. 3. Enhanced production of cytokines and chemokines in TR2 
WT but not inTR2 KO mice, and impaired epithelial proliferation. 
Epithelia were collected from TR2 WT and TR2 KO mice on day 5 
of DSS treatment and amounts of IL-6, MCP-1, IFNγ, TNF-α, IL-4, 
IL-2, IL-10, IL-5 and IL-12-p-70 were quantified using a cytometric 
bead array kit (CBA; BD Biosciences) and a FACS Caliber cytome-
ter. Values are means ± s.d. of triplicate samples. **, P < 0.01, WT 
versus KO mice. 
 
 
and further injected i.p. with the blocking anti-TR2 mAb, 9A3. 
Most of control mice treated with rat IgG were died around 8 
days after the DSS administration while all the mice received 
blocking anti-TR2 mAb survived from the DSS-induced colitis. 
In the initial phase of colitis, both rat IgG- and 9A3 treated mice 
showed comparable level of body-weight loss. However, from 
the fifth day after DSS administration, the body weight loss of 
the mice receiving 9A3 was less severe, while the rat IgG-
treated mice eventually died around day 8 (Fig. 4A). Again the 
control mice had shortened colons (Fig. 4B) with severe ulcera-
tions, distortion of crypts and loss of goblet cells in the colon 
(data not shown). The effects of 9A3 treatment on cytokine 
levels closely resembled those of TR2 KO (Fig. 4C). These 
results demonstrate that 9A3 can modulate the pathology as-




Oral administration of DSS is believed to cause colitis by induc-
ing initial epithelial damage that breaks the important barrier 
function of this cell layer for the luminal contents of the intestine, 
and leads to an inflammatory response. LIGHT/TR2 signaling is 
believed to be involved in the subsequent development of colitis. 
However, the role of TR2 in the colitis has not been clearly 
identified. In this study, we examined the role of TR2 in DSS-
induced colitis using TR2 KO mouse and a TR2 antagonistic 
antibody. 
DSS-treated TR2-/- mice displayed delayed and reduced 
clinical symptoms compared to wild type mice (Fig 1). Histo-
logical analysis demonstrated that the TR2-/- mice seemed to be 
protected from the extensive mucosal destruction, including





























Fig. 4. DSS-induced colitis and the influence of blocking TR2 mAb. (A) DSS-treated mice were injected with 500 µg/ml blockingTR2 mAb i.p. 
on days 0, 2, 4 and 6. Rat IgG was used as control. The mice were administered 3.0% DSS water. Body weight was recorded daily from days 
1 to 20. (B) Photographs of dissected colons of mice treated with rat IgG and antagonist TR2 mAb mice on day 7 after 3.0% DSS water. The 
mice were killed by cervical dislocation, and large intestines with ceca were removed. (C) DSS-induced cytokine expression in mice receiving 
rat IgG or antagonist TR2 mAb. Values are means ± s.d. of triplicate samples. *, P < 0.05, **, P < 0.01, WT versus KO mice. 
 
 
loss of crypts, mucosal erosion, ulcers and inflammatory cell 
infiltration observed in the TR2+/+ mice. Consistent with a previ-
ous report (Dieleman et al., 1994; Stevceva et al., 2001), we 
observed significant increases in numbers of lamina propria 
macrophages, granulocytes, and CD4+ and CD8+ subsets were 
after exposure, of wild type mice to DSS. These cells also in-
creased in the TR2-/- mice, but, the increase was slower (Fig. 2).  
Analysis of cytokines in the colons of DSS-treated wild type 
mice revealed increased levels of TH1 cytokines such as IFN-γ, 
TNF-α, IL-2, and IL-12, and also of TH2 cytokines such as IL-4, 
IL-5, and IL-10, as expected (Scaldaferri and Fiocchi, 2007). 
Although TNF-α, and IFN-γ increases in the colons of TR2-/- 
mice by the 5th day of treatment, their levels were much lower 
than in the wild type. Of the TH1 cytokines, secretion of IL-2 and 
IL-12 was not much lower in the TR2-/- mice (Fig. 3). These 
cytokine pattern were different from those in LIGHT Tg mice, in 
which all of the TH1 cytokines tested, including IFN-γ, IL-12, IL-2, 
and TNF-α, were significantly elevated and were responsible 
for the symptoms (Wang et al., 2005). The results of the cyto-
kine assays suggested that the TH1 response on its own could 
not explain the role of TR2 in DSS induced colitis, as suggested 
for the LIGHT Tg mice. We further analyzed cytokine produc-
tion in the colon and found lower levels of IL-10, and IL-6, as 
well as of the chemokine, MCP-1, in the colons of TR2-/-mice 
than in those of wild type mice. IL-6 is reported to be involved in 
IBD, since it induces T cell accumulation via an antiapoptotic 
signal (Mudter and Neurath, 2007). IL-10 deficient mouse have 
been found to display reduced symptom of colitis due to elimi-
nation of local macrophages (Watanabe et al., 2003). MCP-1 is 
also important in colitis since MCP-1 deficient mice showed a 
significant reduction in the severity of colitis as a consequence 
of down-regulation of IL-1B, and IFN-γ (Khan et al., 2006). In 
this report, we have demonstrated that not only TH1 cytokines 
such as TNF-α, and IFN-γ (Wang et al., 2005), but also IL-6, 
MCP-1, and IL-10, are important in the immune responses 
mediated by TR2 in colitis induced by DSS.  
Administration of DSS is known to damage epithelial cells, 
and the proliferation of cells in colonic crypts is decreased 
(Strober et al., 2002). In the colon of TR2-deficient mice, super-
ficial epithelial injury induced by DSS adsorption is reduced and 
the rate of healing is accelerated. To reestablish mucosal integ-
rity, epithelial cells need to proliferate to replace the reduced 
cell populations. Since measurements of BrdU incorporation 
showed that BrdU-positive cells were mainly localized to the 
crypt regions of TR2-/- mice (Fig. 1D), it appears that the epithe-
lial cells of TR2-/- mice recover more efficiently from DSS-
induced damage due to stimulation of the proliferation of epithe-
lial cell precursors. These results are consistent with an early 
report that low concentrations of TNF-α, IFN-γ, IL-6, and IL-10 
are important mediators of tissue repair and restitution after 
nonspecific colonic injury (Dieleman et al., 1996). 
Our results demonstrated that a deficiency of TR2 retarded 
the progress of inflammation in DSS-induced colitis, and this 
finding was confirmed using an antagonistic antibody against 
TR2 which was seem to modulate the pathology associated 
with TR2 in vivo (Fig. 4).  
In summary, we have clarified the roles of TR2 signaling in 
the maintenance of intestinal homeostasis. Knockout of TR2 
has the effect of protecting mucosal integrity, suppressing in-
nate and adaptive immunity in response to DSS.  
 
Note: Supplementary information is available on the Molecules 
and Cells website (www.molcells.org). 
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